Depression and pain: the need for a new screening tool (full article)

There is a strong association between pain and depression, and the presence of pain negatively affects the recognition and treatment of depression. Here, Dr Cocksedge and colleagues’ explore the neurobiology behind this relationship and propose a new screening tool to assess patients with either condition for the coexistence of the other, with the potential for significantly better diagnosis, referral and hence treatment.

In both the ICD10 and DSM IV definitions of depression, pain is briefly mentioned as a possible symptom but is certainly not considered as a defining symptom such as low mood or as a somatic symptom. This is surprising since pain symptoms and depression commonly coexist, as has been demonstrated in a number of studies (see Table 1). Not only does there appear to be a clear association between pain and depression, but furthermore, there is a recognised concern that the presence of pain often negatively affects the recognition and treatment of depression: depressed patients have been shown to be far more likely to present with pain symptoms than they are to present with affective symptoms1 and it has been estimated that if all patients from general practice who presented with painful conditions were evaluated for possible depression, then 60% of previously undetected depressive cases would have been recognised.2 Furthermore, when depression is recognised to be present in conjunction with pain, clinicians are more likely to focus on treating the pain and are less likely to consider psychological treatments, leading to worse outcomes.1

Table 1

Table 1. Examples of the studies showing an association between depression and pain

The situation is further complicated by the fact that the subjective experience of pain is likely to have cognitive, emotional and behavioural components in addition to the underlying biological component and, in some cases, there may be no underlying biological component at all. It is likely to be very difficult to distinguish between these components, but for the purposes of considering the effect of pain on depression, the origin of the pain probably makes little difference to the established association.

When pain and depression are recognised and the clinician does focus on treating the depression, the presence of pain appears to increase the resistance of depression to treatment (see Table 2 in the online version of this article). As might well be expected, a combined diagnosis of both pain and depression accounts for a far greater healthcare resource utilisation in both primary and secondary care, since patients with both pain and depression have an increased number of GP visits, an increased rate of investigations, a higher rate of antidepressant drug switching and increased referral to secondary care.3 The combination of both pain and depression also has an additive effect on the work days lost through both sickness absence and productivity.4

Table 2

Table 2. The effect of chronic pain on the efficacy of treatment for depression

Aim

We looked to identify if there were any combined pain and depression tools by using a comprehensive literature search. We examined our search results to help outline and propose a future mechanism of screening for comorbidity of depression and pain in a primary care setting.

Method

We conducted an extensive literature search to investigate if any screening tools simultaneously could screen patients for both depression and pain. This was undertaken with a systematic MEDLINE, EMBASE and AMED search over the years 1946–2015 using the combined terms ‘pain’ AND ‘depression’ combined with the individual terms ‘screening’, ‘checklist’, ‘tool’, ‘questionnaire’, ‘inventory’ or ‘scale’.

Results

From our literature search, we found a total of 43 articles but none offered a combined general screening tool for depression and pain. The articles were analysed and divided into relevant subsections. The majority focussed on eliciting an altered mental state in conditions with known chronic pain. Two articles, however, did assess for both depression and pain: Tamiya et al.5 looked at pain, anxiety and depression in 145 Japanese women with rheumatoid arthritis. They used visual analogue scales to measure depression and anxiety and compared these with standard measures and to a pain analogue scale. However, their study was restricted to patients with rheumatoid arthritis, a long-term condition where pain is central to the presentation, and was not replicated in other populations of chronic conditions. Furthermore, the sample population was selective and the tools used as diagnostic as opposed to screening. Luppi et al.6 looked at pain, anxiety and depression in 81 patients with leukaemia and 118 patients with solid cancers. They used a Likert scale (0–10) for pain, depression and anxiety and compared these with standard measures for depression and anxiety. However, again their study was restricted to patients with a specific condition – malignancy – and was not replicated in other chronic conditions.

We also found a further similar study, not from within our search criteria, which employed a visual analogue scale to elicit anxiety, depression and catastrophising in 45 patients with neck pain.7 Again, as with Tamiya et al., the study was restricted to a single presentation of pain, used small numbers and crucially was not tested as a screening tool. In summary, our search did not reveal any validated tool which could be used to screen for comorbid pain and clinical depression in primary care. In the absence of such a combined tool, we then considered common screening tools in use for depression and pain separately.

There are a number of well recognised screening tools for depression. In the general practice setting, three tools are recommended in the Quality and Outcomes Framework (QOF) guidance for the evaluation of depression. Furthermore, for patients with a chronic physical health problem in primary care, NICE guidelines recommend two standard questions about depression are asked to all patients and if either answers are positive, then to conduct further questioning.8 These different screening tools can be compared with the ‘gold standard’ for rating depression in clinical research, the Hamilton Rating Scale for Depression.9

There are also a number of screening tools for pain, although those designed specifically for use in primary care settings tend to be specific to particular types of pain such as back pain, knee pain or neuropathic pain.

Discussion

The neurobiological hypothesis of the coexistence of pain and depression

Physical pain can be considered to be a combination of the sensory component of the pain and the associated affective component of the pain. Although psychological pain, such as psychological distress, does not involve a painful stimulus, it still signals a threat to the body in the same way as physical pain and thus the neural mechanisms, including the hypothalamic-pituitary axis, are still activated as part of the stress response. It has been shown that the nociceptive pathway for psychological pain is in fact similar to the pathway involved in the processing of the affective component of physical pain.10 Through this mechanism, it is hardly surprising therefore that pain and depression are associated.

More specifically, the association can be considered in terms of commonality of neurotransmitters. It has long been accepted that, biochemically, depression can be attributed to a deficiency in serotonin, noradrenaline and dopamine. There is now increasing understanding of the descending system of pain modulation whereby the periaqueductal grey acts as a relay between forebrain and midbrain structures and the brainstem.11 Within this relay are serotonergic and noradrenergic neurons which dampen pain signals transmitted from the periphery by depressing the activity of nociceptive neurons in the spinal dorsal horn.11, 12 This system serves to determine our affect and attention to stimuli and usually modulates this so we are able to focus more on external stimuli rather than those from within the body.13 However, in the scenario of a deficiency of serotonin and noradrenaline, this system likely loses its modulatory effect such that in depression, multiple pain symptoms are experienced and the presence of pain leads to increased focus on the pain and a lowered affect. This hypothesis has been demonstrated experimentally in a recent study comparing patients with chronic pain in fibromyalgia with and without depression, which showed that inhibition of pain (via the diffuse noxious inhibitory controls [DNIC]) is further reduced in comorbid depression.14

Recent studies have highlighted that the central nervous system undergoes long-term plasticity in the presence of chronic pain and depression. The underlying neural circuitry and molecular signalling pathways that underlie this are beginning to be understood.15 The molecular signalling pathways include not only the neuropeptides serotonin, noradrenaline and dopamine as described above, but also include a role for glutamate signalling, neurotrophic factors (eg brain-derived neurotrophic factor [BDNF]) and neuromodulatory lipids (eg endocannabinoids).15 It seems likely that these complex changes, which result from chronic pain and depression together, are at the root of why chronic pain and depression together are so difficult to treat; but further work is needed in this area.

Treating the problem

If pain and depression share common deficiencies in neurotransmitters, then it seems logical to suggest that antidepressant therapy, which boosts these neurotransmitters, could be used in the treatment of pain. To this end, it has long been recognised that tricyclic antidepressants have a role in treating chronic pain.16 More recently, an evidence-based review of using antidepressants in chronic pain showed that serotonergic-noradrenergic antidepressants appear to be more effective than serotonergic antidepressants.17 One specific serotonergic-noradrenergic antidepressant that is becoming increasingly popular is duloxetine. The effectiveness of duloxetine in treating chronic pain was reviewed recently in a 2014 Cochrane review,18 which focussed on the use of this medication in treating painful neuropathy, chronic pain and fibromyalgia. The authors concluded that there was a significant improvement in pain in all three types of condition, but with the evidence being strongest in diabetic neuropathy. It is of particular interest that of all the different types of pain, it is neuropathic pain, rather than acute or inflammatory pain, that is most successfully treated with antidepressants. Using a model of neuropathic pain employing peripheral nerve injury, it has been shown in rodents that this type of pain can induce depressive-type symptoms, including anhedonia and behavioural despair.15

Of course, in patients presenting with chronic pain and depression, an antidepressant is not the only solution. Many of the cognitive, behavioural and affective factors that are critical in the development of depression are also relevant to the development of chronic pain, which helps to further explain their association. Hence, a patient with both depression and pain needs a multidisciplinary approach to the problem from psychiatrists, psychologists and pain specialists with an understanding, empathetic style and inclusion of education for patients and their families about how the two conditions are likely to be linked.19 There is a wealth of evidence to suggest that non-pharmacological interventions such as cognitive behavioural therapy, behavioural therapy and acceptance-based therapy have some effect in treating chronic pain and improving mood outcomes.20–22 More recent work has demonstrated functional neuroimaging changes in chronic pain patients (in the Default Mode Network) which can be altered by these interventions and correlate with clinical outcomes.23

Addressing the problem: the need for a new screening tool

Whilst it is encouraging that we are beginning to understand the association between depression and pain, the likely mechanisms involved and possible treatment options, it is of little help to the typical patient if the coexistence of the two conditions is frequently missed. Instead, what is really needed is a simple-to-use screening tool for any patient presenting to a general practitioner with either pain or depression alone, to assess if the two coexist. In the cases where coexistence is demonstrated, the patient can then be treated appropriately with consideration of both problems simultaneously.

The fact that such a screening tool does not yet exist is surprising since untreated depression may adversely affect ability to treat pain and disease-specific outcomes. Therefore, the argument for including pain screening when assessing patients with long-term conditions for depression is strong.24

Work is clearly needed to develop and validate a combined screening tool for both pain and depression for use with patients suffering from long-term physical health conditions. Here we consider the patient presenting to primary care with a long-term physical health condition. There are separate screening tools that could be used to investigate the presence of either depression or pain alone but we suggest that using an integrated, combined tool will ensure consistency in the primary care approach to long-term health conditions. Our choice of a suitable integrated tool must also consider the time pressures within general practice where it would not be practical to use a combined version of two lengthy screening tools. To this end, we note that since NICE recommends that patients with such conditions are all screened for depression, by asking two standard screening questions, we feel that the simplest and least time-consuming option to incorporate pain screening for these patients is to add a third screening question about pain. The NICE guidelines further recommend that if either question regarding depression screens positive, then further questions are asked to clarify the situation. We therefore recommend that an additional two questions could be added for those who screen positive for pain, which ask about the nature and the severity of the pain. With consideration of the various pain scales and of the time constraints within general practice, we feel that the best option is to use the numerical rating scale (0–10) as the means to assess the pain severity. Our recommended approach is illustrated in Figure 1, the findings of which could be recorded electronically within the patient notes. We suggest that including pain screening as part of depression screening in patients with long-term physical health conditions will ensure that any potential pain component is not overlooked. This thereby ensures that in the cases of any identified depression complicated by the presence of pain, the treatment of this pain is incorporated into the treatment of the depression and is therefore more likely to be successful.

Figure 1

Figure 1. Recommended approach for pain and depression screening for patients with long-term physical health conditions presenting to the general practitioner

We suggest that this simple screening tool could be used by a practice nurse as part of the annual review of any chronic illness. Should the three screening questions or the further questions used thereafter suggest the existence of newly identified chronic pain and / or depression, then the patient could be referred to the general practitioner for further discussion and treatment if necessary. In future work we plan to test the feasibility of this screening tool in correctly identifying new cases of pain and / or depression in chronic illness and later, the effect that this earlier identification can have on outcomes.

Summary

There is a strong association between pain and depression and the presence of pain negatively affects the recognition and treatment of depression. Their coexistence suggests a shared neurobiology. Early recognition and treatment of this comorbidity could have significant impact on patient outcomes and health service costs. Failure to do so could lead to treatment resistance, negative clinical and social impact and increased costs to health and social sectors. It is thus imperative that this comorbidity be recognised early to allow specialist treatment options to be considered, including the use of serotonergic- noradrenergic antidepressants.

Sadly, at the present time, patients presenting with pain alone are not commonly screened for depression and conversely, patients presenting with depression alone are not commonly screened for the coexistence of pain. It is surprising that a single screening tool to assess patients with either condition for the coexistence of the other has not yet been developed. We believe that such a screening tool would lead to significantly better diagnosis, referral and hence treatment. We believe that we have presented the evidence to suggest an easy-to use self-reported screening tool for patients presenting to their general practitioner with chronic illness to screen for both depression and pain. This could also be used in the context of patients presenting either with pain or depression to screen for the presence of both conditions.

Dr Cocksedge is CT3 in Psychiatry at Cornwall Partnership NHS Foundation Trust; Dr Shankar is a Consultant Neuropsychiatrist at Cornwall Partnership NHS Foundation Trust in Truro, and Honorary Associate Clinical Professor at Plymouth and Exeter Medical School, and Dr Simon is a GP at Bearwood Medical Centre in Bournemouth, Executive Editor – Innovait, and Editor, Oxford Handbook of General Practice.

Declaration of interests

No conflicts of interest were declared.

References

1. Bair MJ, Robinson RL, Katon W, et al. Depression and pain comorbidity: a literature review. Arch Intern Med 2003;163:2433–45.
2. Katon W. Depression: Relationship to somatization and chronic medical illness. J Clin Psychiatry 1984;45:4–12.
3 Watson L, Baird J, Hösel V, et al. The effect of concurrent pain on the management of patients with depression: an analysis of NHS health care resource utilization using the GPRD database. Int J Clin Practice 2009;63:698–706.
4. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Comorbid painful physical symptoms and depression: prevalence, work loss, and help seeking. J Affect Disord 2006;92:185–93.
5. Tamiya N, Araki S, Ohi G, et al. Assessment of pain, depression, and anxiety by visual analogue scale in Japanese women with rheumatoid arthritis. Scand J Caring Sci 2002;16:137–41.
6. Luppi M, Zanin R, Morselli M, et al. Comparison of symptom burden (pain, anxiety, depression) in patients with leukemia versus patients with solid tumors at diagnosis: Ideal cut-off points for screening by ESAS. Poster presented at the 15th Congress of the European Hematology Association, EHA 2010 Barcelona, Spain. Haematologica 2010;95(Suppl 2):190–1.
7. Dimitriadis Z, Strimpakos N, Kapreli E, et al. Validity of Visual Analog Scales for Assessing Psychological States in Patients with Chronic Neck Pain. J Musculoskelet Pain 2014 doi:10.3109/10582452. 2014.907852.
8. National Institute for Health and Care Excellence. Depression with a chronic physical health problem: recognition and management. Clinical Guideline CG91. London: NICE, 2009.
9. Cameron IM, Cardy A, Crawford JR, et al. Measuring depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D and BDI-II. Br J Gen Pract 2011;61:419–26.
10. Meerwijk EL, Ford JM, Weiss SJ. Brain regions associated with psychological pain: implications for a neural network and its relationship to physical pain. Brain Imaging Behav 2013;7:1–14.
11. Fields HL. Pain modulation: expectation, opioid analgesia and virtual pain. Prog Brain Res 2000;122:245–53.
12. Hirakawa N, Tershrer SA, Fields HL. Highly delta selective antagonists in the RVM attenuate the antinociceptive effect of PAG DAMGO. Neuroreport 1999;10:3125–9.
13. +Stahl SM. Does depression hurt? J Clin Psychiatry 2002;63:273–4.
14. de Souza JB, Potvin S, Goffaux P, et al. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin J Pain 2009;25:123–7.
15. Doan L, Manders T, Wang J. Neuroplasticity underlying the comorbidity of pain and depression. Neural Plast 2015;2015:504391.
16. Lee R, Spencer PS. Antidepressants and pain: a review of the pharmacological data supporting the use of certain tricyclics in chronic pain. J Int Med Res 1977;5:146–56.
17. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000;32:305–16.
18. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014;1:CD007115. doi: 10.1002/14651858.CD007115.pub3.
19. Katona C, Peveler R, Dowrick C. Pain symptoms in depression: definition and clinical significance. Clin Med 2005;5:390–5.
20. Bernardy K, Füber N, Köllner V, et al. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome — a systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2010;37:1991–2005.
21. Veehof MM, Oskam MJ, Schreurs KM, et al. Acceptance-based interventions for the treatment of chronic pain: a systematic review and meta-analysis. Pain 2011;152:533–42.
22. Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev 2012;11:CD007407. doi: 10.1002/14651858.CD007407.pub3.
23. Shpaner M, Kelly C, Lieberman G, et al. Unlearning chronic pain: A randomized control trial to investigate changes in intrinsic brain connectivity following Cognitive Behavioral Therapy. NeuroImage: Clinical 2014;5:365–76.
24. Cocksedge KA, Simon C, Shankar R. A difficult combination: Chronic physical illness, depression and pain. Br J Gen Pract 2014;64:440–1.
25. Patten SB. Long-term medical conditions and major depression in a Canadian population study at waves 1 and 2. J Affect Disord 2001;63:35–41.
26. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry 2003;60:39–47.
27. Arnow BA, Hunkeler EM, Blasey CM, et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 2006;68:262–8.
28. Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, et al. Relationships among pain, anxiety, and depression in primary care. Depress Anxiety 2008;25:593–600.
29. Demyttenaere K, Reed C, Quail D, et al. Presence and predictors
of pain in depression: results from the FINDER study. J Affect Disord 2010;125:53–60.
30. Bair MJ, Brizendine EJ, Ackermann RT, et al. Prevalence of pain and association with quality of life, depression and glycaemic control in patients with diabetes. Diabet Med 2010;27:578–84.
31. Beesdo K, Jacobi F, Hoyer J, et al. Pain associated with specific anxiety and depressive disorders in a nationally representative population sample. Soc Psychiatry Psychiatr Epidemiol 2010;45:89–104.
32. Kroenke K, Wu J, Bair MJ, et al. Reciprocal relationship between pain and depression: a 12-month longitudinal analysis in primary care. J Pain 2011;12:964–73.
33. Gerrits MM, van Oppen P, van Marwijk HW, et al. Pain and the onset of depressive and anxiety disorders. Pain 2014;155:53–9.
34. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004; 66:17–22.
35. Karp JF, Scott J, Houck P, et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry 2005;66:591–7.
36. DeVeaugh-Geiss AM, West SL, Miller WC, et al. The adverse effects of comorbid pain on depression outcomes in primary care patients: results from the ARTIST trial. Pain Med 2010;11:732–41.
37. Kent P, Mirkhil S, Keating J, et al. The concurrent validity of brief screening questions for anxiety, depression, social isolation, catastrophization, and fear of movement in people with low back pain. Clin J Pain 2014;30:479–89.
38. Kongsted A, Aambakk B, Bossen S, et al. Brief screening questions for depression in chiropractic patients with low back pain: identification of potentially useful questions and test of their predictive capacity. Chiropr Man Therap 2014;22:4.
39. Lopez MN, Pierce RS, Gardner RD, et al. Standardized Beck Depression Inventory-II scores for male veterans coping with chronic pain. Psychol Serv 2013;10:257–63.
40. Poole H, Bramwell R, Murphy P. The utility of the Beck Depression Inventory Fast Screen (BDI-FS) in a pain clinic population. Eur J Pain 2009;13:865–9.
41. Cheour M, Ellouze F, Zine I, et al. Beck inventory depression assessment in chronic pain patients. Tunis Med 2008;86:1074–8.
42. Lee Y, Lin PY, Hsu ST, et al. Comparing the use of the Taiwanese Depression Questionnaire and Beck Depression Inventory for screening depression in patients with chronic pain. Chang Gung Med J 2008;31:369–77.
43. Sela RA. Screening for depression in palliative cancer patients attending a pain and symptom control clinic. Palliat Support Care 2007;5:207–17.
44. Haggman S, Maher CG, Refshauge KM. Screening for symptoms of depression by physical therapists managing low back pain. Phys Ther 2004;84:1157–66.
45. Nakaigawa Y, Kasuda H, Fukuda H, et al. Psychological evaluation of out-patients in our pain clinic using self-rating depression scale and state-trate anxiety inventory questionnaire. Masui 1995;44: 362–6.
46. Wulsin LR, Hillard JR, Geier P, et al. Screening emergency room patients with atypical chest pain for depression and panic disorder. Int J Psychiatry Med 1988;18:315–23.
47. Turner JA, Romano JM. Self-report screening measures for depression in chronic pain patients. J Clin Psychol 1984;40:909–13.
48. Choi Y, Mayer TG, Williams MJ, et al. What is the best screening test for depression in chronic spinal pain patients? Spine J 2014;14:1175–82.
49. Olaya-Contreras P, Persson T, Styf J. Comparison between the Beck Depression Inventory and psychiatric evaluation of distress in patients on long-term sick leave due to chronic musculoskeletal pain. J Multidiscip Healthc 2010;3:161–7.
50. Geisser ME, Roth RS, Robinson ME. Assessing depression among persons with chronic pain using the Center for Epidemiological Studies- Depression Scale and the Beck Depression Inventory: a comparative analysis. Clin J Pain 1997;13:163–70.
51. Harris CA, D’Eon JL. Psychometric properties of the Beck Depression Inventory – second edition (BDI-II) in individuals with chronic pain. Pain 2008;137:609–22.
52. Poole H, Bramwell R, Murphy P. Factor structure of the Beck Depression Inventory II in patients with chronic pain. Clin J Pain 2006;22:790–8.
53. Morley S, Williams AC, Black S. A confirmatory factor analysis of the Beck Depression Inventory in chronic pain. Pain 2002;99:289–98.
54. Wesley AL, Gatchel RJ, Garofalo JP, et al. Toward more accurate use of the Beck Depression Inventory with chronic back pain patients. Clin J Pain 1999;15:117–21.
55. Novy DM, Nelson DV, Berry LA, et al. What does the Beck Depression Inventory measure in chronic pain?: a reappraisal. Pain 1995;61:261–70.
56. Chibnall JT, Tait RC. The short form of the Beck Depression Inventory: validity issues with chronic pain patients. Clin J Pain 1994;10:261–6.
57. Krefetz DG, Steer RA, Jermyn RT, et al. Screening HIV-infected patients with chronic pain for anxiety and mood disorders with the beck anxiety and depression inventory-fast screens for medical settings. J Clin Psychol Med Settings 2004;11:283–9.
58. Riggs RM, McCarthy JM, Kaufman L. The utility of the Beck Depression Inventory in the evaluation of chronic pelvic pain patients: Commentary. Obstetrical and Gynecological Survey 2008;63:148–9.
59. Riggs RM, McCarthy JM, Kaufman L. The utility of the Beck Depression Inventory in the evaluation of chronic pelvic pain patients. J Gynecologic Surg 2007;23:127–32.
60. Bishop SR, Edgley K, Fisher R, et al. Screening for depression in chronic low back pain with the Beck Depression Inventory. Can J Rehabil 1993;7:143–8.
61. LaVonne WA, Gatchel RJ, Garofalo JP, et al. Towards more accurate use of the Beck Depression Inventory with chronic back pain patients. Clin J Pain 1999;15:117–21.
63. Logan DE, Claar RL, Guite JW, et al. Factor structure of the children’s depression inventory in a multisite sample of children and adolescents with chronic pain. J Pain 2013;14:689–98.
63. Soares-Filho GL, Freire RC, Biancha K, et al. Use of the hospital anxiety and depression scale (HADS) in a cardiac emergency room: chest pain unit. Clinics (Sao Paulo) 2009;64:209–14.
64. Castro MM, Quarantini L, Batista-Neves S, et al. Validity of the hospital anxiety and depression scale in patients with chronic pain. Rev Bras Anestesiol 2006;56:470–7.
65. Kuijpers PM, Denollet J, Lousberg R, et al. Validity of the hospital anxiety and depression scale for use with patients with noncardiac chest pain. Psychosomatics 2003;44:329–35.
66. Di Vadi PP, Dobson C, Bunton T, et al. Use of the brief pain inventory and hospital anxiety/depression scale questionnaires in a district general hospital pain clinic. The Pain Clinic 2006;18:225–9.
67. Bagnato G, Atteritano M, Sorbara S, et al. Pain intensity and threshold in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis patients: Correlations with the Hamilton depression rating scale. Ann Rheum Dis 2013;72:Suppl 3 A344 doi:10.1136/annrheumdis- 2013-eular.1061.
68. Trudeau J, Turk D, Dworkin R, et al. Validation of the Hospital Anxiety and Depression Scale (HADS) in patients with acute low back pain. J Pain 2012;13:S24.
69. Lynch T, O’Connor L, Hassett A. Hospital anxiety and depression scale predicts response to ketamine infusion therapy in patients with chronic pain. Eur J Pain Suppl 2011;5:235.
70. Bagnato G, De Andres I, Sorbara S, et al. Pain threshold and intensity in rheumatic patients: correlations with the Hamilton Depression Rating scale. Clin Rheumatol 2015;34:555–61.
71. Karp JF, Rudy T, Weiner DK. Persistent pain biases item response on the Geriatric Depression Scale (GDS): preliminary evidence for validity of the GDS-PAIN. Pain Med 2008;9:33–43.
72. Sarda J Jr, Nicholas MK, Pimenta CA, et al. Psychometric properties of the DASS-Depression scale among a Brazilian population with chronic pain. J Psychosom Res 2008;64:25–31.
73. Taylor R, Lovibond PF, Nicholas MK, et al. The utility of somatic items in the assessment of depression in patients with chronic pain: a comparison of the Zung Self-Rating Depression Scale and the Depression Anxiety Stress Scales in chronic pain and clinical and community samples. Clin J Pain 2005;21:91–100.
74. Olaya-Contreras P, Styf J, Lundberg M, et al. Measurements invariance for gender and psychometric properties of the Depression, Anxiety and Positive Outlook Scale (DAPOS) in chronic musculoskeletal pain. Eur J Pain 2009;13:S227a–27.
75. Peek L, Sawyer JP. Utilization of the family drawing depression scale with pain patients. The Arts in Psychotherapy 1988;15:207–10.
76. Jardri R, Maron M, Delion P, et al. Pain as a confounding factor in postnatal depression screening. J Psychosom Obstet Gynecol 2010;31:252–5.
77. Maron M, Jardri R, Delion P, et al. Pain in the early postpartum and postnatal depression screening: Symptom or confounding factor. Archives of Women’s Mental Health 2011;14:S35.
78. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13.
79. Arbisi, PA. Review of the Beck Depression Inventory II. In: Plake BS, Impara JC, eds. The supplement to the thirteenth mental measurements yearbook. Lincoln, NE: The Buros Institute of Mental Measurements, 1999;13–16.
80. Zigmond AS, Snaith P. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–70.
81. Marinus J, Leentjens AF, Visser M, et al. Evaluation of the Hospital Anxiety and Depression Scale in patients with Parkinson’s disease. Clin Neuropharmacol 2002;25:318–24.
82. Beck AT, Steer RA, Ball R, et al. Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588–97.
83. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
84. Williamson A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin Nurs 2005;14:798–804.
85. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129–38.

Table 3

Table 3. The results of the literature search* to investigate if any screening tools simultaneously could screen patients for both depression and pain (*A MEDLINE search was done for articles combining the terms ‘pain’ AND ‘depression’ combined with the individual terms ‘screening’, ‘checklist’, ‘tool’, ‘questionnaire’, ‘inventory’ or ‘scale’. A total of 28 citations were found and are listed, subdivided into categories)

Table 4

Table 4. Three tools used in the general practice setting to screen for depression, as recommended in the Quality and Outcomes Framework (QOF) guidance, and the NICE screening questions for depression in patients with chronic illness, compared with the recognised ‘gold standard’ in clinical research, the Hamilton Rating Scale for Depression

Table 5

Table 5. Examples of common generalised pain scales in use which could be used in a primary care setting

Depression and pain the need for a new screening tool

Add yours ↓
Web design and marketing agency Leamington Spa